References
- Stamler J: Epidemiology of hypertension: Achievements and challenges. In Moser M (Editor): Hypertension: A Practical Approach. Boston, Little, Brown & Co, 1975. pp 1–43
- Fries E: Veterans Administration Cooperative Study Group on Antihypertensive agents: Effects of treatment on morbidity in hypertension. I. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202:1028–1034, 1967
- Gifford R Jr: Practical clinical pharmacology of antihypertensive drugs. In Vidt D (Editor): Cleveland Clinic Cardiovascular Consultations. Philadelphia, FA Davis Co, 1975, pp 143–156
- Hayes AH Jr: Clinical pharmacology of current and experimental drugs. In Moser (Editor), pp 89–114
- Kaplan N: Clinical Hypertension. New York, Medcom, Inc, 1973, pp 95–157
- Melmon K: The clinical pharmacology of commonly used antihypertensive drugs. In Melmon K (Editor): Cardiovascular Drug Therapy. Philadelphia, FA Davis Co, 1974, pp 175–197
- Finnerty F: Hypertensive emergencies. In Laragh J: Hypertension Manual. New York, Yorke Medical Books, pp 801–820
- Gifford R Jr: Hypertension: A practical guide to medical management. In: The Hypertension Handbook. West Point, Pa, Merck Sharp & Dohme, 1974, pp 83–112
- Koch-Weser J: Correlation of pathophysiology and pharmacotherapy in primary hypertension. In Laragh (Editor),7 pp 759–785
- Moser M: Management of essential hypertension. In Moser (Editor), pp 115–149
- Pettinger W. Mitchell HC: Minoxidil: An alternate to nephrectomy for refractory hypertension. N Engl J Med 289:167–171, 1973
- LeSher D. Harris L, Hawkinson R: Comparison of bid vs qid hydralazine dosage regimens in hypertensive patients on multiple drug therapy. (Abstr) Clin Pharmacol Ther 19:110–111, 1976
- Mack TM, Henderson BE, Gerkins VR. et al: Reserpine and breast cancer in a retirement community. New Engl J Med 292:1366–1371, 1975
- O'Fallon. WM, Labarthe DR. Kurland LT: Rauwolfia derivatives and breast cancer. Lancet 2:292–296, 1975
- Laska EM, Siegal C, Meisner M. et al: Matched-pairs study of reserpine use and breast cancer. Lancet 2:296–300, 1975
- Bühler FR, Laragh JH, Baer L, et al: Propranolol inhibition of renin secretion: A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 287:1209–1214. 1972
- Bühler FR, Laragh JH, Vaughan ED, et al: Antihypertensive action of propranolol: Specific anti-renin responses in high and normal renin forms of essential renal, renovascular and malignant hypertension. Am J Cardiol 32:511–522, 1973
- Stokes GS, Weber MA, Thornell IR: Beta-blockers and plasma renin activity in hypertension. Br Med J 1:60–62, 1974
- Leonetti C, Mayer G, Morganti A, et al: Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. Clin Sci Mol Med 48:491–499, 1975
- Bravo EL, Tarazi RC, Dustan HP, et al: Dissociation between renin and arterial pressure responses to beta- adrenergic blockage in human essential hypertension. Circ Res 36:(Suppl) 1–241–247, 1975
- Bühler RF. Burkart F, Lutold BE, et al: Antihypertensive beta blocking action as related to renin and age: A pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 36:653–669, Oct, 1975
- Dollery CT, Lewis PH, Myers MG: Central hypotensive effect of propranolol in the rabbit. Br J Pharmocol 48:343P, 1973
- Adanropoulos PM, Chrysanthakopoulis SG, Frohlick ED: Systolic hypertension: Nohomogeneous diseases. Am J Cardiol 36:697–701, 1975
- Warren DJ: Beta-adrenergic receptor blockade and renal function. AM Heart J 91:265–266, 1976
- Hornych A, Safar M, Papanicolaou N, et al: Renal and cardiovascular effect of prostaglandins A2 in hypertensive patients. Eur J Clin Invest 3:391, 1973
- Douglas W: Polypeptides-angiotensin, plasma kinins, and other vasoactive agents: Prostaglandins. In Goodman L, Gilman A: The Pharmacologic Basis of Therapeutics. Ed 5. New York. The Macmillan Co, 1975, pp 636–637